MONJUVI (tafasitamab-cxix) for injection
MONJUVI (tafasitamab-cxix) is a prescription medicine used in combination with lenalidomide to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). FDA approved tafasitamab-cxix (brand name MONJUVI) is not (yet) registered or available in India. The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities.
Home | tafasitamab-cxix for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
MONJUVI (tafasitamab-cxix) for injection
Tafasitamab, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma.
MONJUVI is a prescription medicine given:
• in combination with lenalidomide, to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
• in combination with a lenalidomide and rituximab, to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children
Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.
Drug (Brand / Generic): MONJUVI® (tafasitamab-cxix) for injection, for intravenous use Initial U.S. Approval: 2020
Current Indication: treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Approval Date: 2020
For injection: 200 mg of tafasitamab-cxix as lyophilized powder in single-dose vial for reconstitution.
Find Reference Updates
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
MONJUVI (tafasitamab-cxix) for injection is generally considered a specialty medicine and may require specialized handling and distribution procedures. Where legally permitted, it may be sourced through international supply channels and transported under temperature-controlled conditions (2°C to 8°C) to maintain product integrity.
Patients and healthcare providers seeking information about access to this medicine may consult organizations that assist with administrative processes related to importation, documentation, customs procedures, and cold-chain logistics, subject to applicable laws, regulations, and product availability.
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. Alleviare Life Sciences is one such organization that may provide support services related to documentation, customs coordination, and temperature-controlled transportation. Patients should consult their treating physician and verify all regulatory requirements before pursuing access to any imported medicine.
Get in touch with support team of Alleviare Life Sciences Pvt. Ltd. to learn about available patient access and import facilitation options.
Contact the facilitator: Mr. Kamal
Address: Mezzanine Floor, S-9, Green Park Extension, South Delhi, Delhi, 110016
Call: @ +91-9289711087 / 9289711088
WhatsApp: @ +91-9289711087 / 9289711088
Email: info@alleviareindia.com
Website: www.alleviareindia.com
Get access to FDA approved medicines in India.
On request of patient, we have facilitated patient in import process to get delivered in time. If patients from following city in India looking for speciality medicines can contact us for the same – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
Who facilitates the import of restricted and internationally sourced anti-cancer medicines into India?
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. We provides support and guidance regarding patient-specific medicine access pathways, subject to applicable regulatory requirements and healthcare provider recommendations. Contact us to learn more about the available processes and documentation requirements.
If you’re considering MONJUVI, We can outline the exact documents and process typically used for a Form 12A/Form 12B application.
Looking for access to overseas or restricted anti-cancer medicines in India?
We facilitates patient specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B import permit.
How much does MONJUVI cost in the India?
Kindly contact us to confirm the current price and availability of MONJUVI (tafasitamab-cxix) for injection. Product pricing is generally based on the manufacturer’s listed price and may be subject to change without notice. Additional charges, including Named Patient support fees, shipping costs, and applicable local taxes, may apply. Final pricing and availability will be confirmed at the time of inquiry.
What documents are required to import MONJUVI to India?
To legally initiate the import process, you or your representative must compile the following paperwork: Valid Prescription, Form 12A Application, Medical Records, Patient Identity Proof.
How can patients in India access imported MONJUVI?
Alleviare facilitates access to patient-specific medicines through applicable regulatory pathways, including the Named Patient Program, where permitted under Indian law and subject to the necessary approvals, documentation, and import permissions issued by the relevant authorities.
How can patients access medicines that are not yet approved or registered in India?
The medicines referenced on this website may not be approved for commercial marketing or general distribution in India. Any access, where permitted, is intended solely for an individual patient pursuant to a valid prescription and under the supervision of a qualified healthcare professional.
Is MONJUVI currently available in India?
As of June 2026, MONJUVI (tafasitamab-cxix) for injection is not generally approved for routine marketing in India by the Indian regulator (CDSCO), based on currently available public information.
However, Indian patients may be able to access it through a Named Patient Import / Named Patient Program pathway when prescribed by an oncologist and imported for a specific patient.
Is tafasitamab-cxix available in India?
No, FDA approved tafasitamab-cxix (brand name MONJUVI) is not (yet) registered or available in India but on request Indian patient can get access.
Alleviare will help patient / doctor to get in India.
What regulatory requirements apply to accessing medicines not yet approved in India?
Personal-use / Named Patient Import (most common pathway)
For an individual patient, the primary route is import for personal use under Rule 36 of the Drugs and Cosmetics Rules, 1945. A treating physician must prescribe the medicine, and an application is made to CDSCO in Form 12A. If approved, CDSCO issues a Form 12B permit authorizing import of a limited quantity for that specific patient.
How can eligible patients explore access to blood cancers medicines not currently approved in India?
Eligible patients may discuss potential treatment options with their treating oncologist and explore available patient-specific access pathways for certain blood cancers medicines that are not currently approved or commercially available in India. Access, where applicable, is subject to physician recommendation, regulatory requirements, and relevant documentation.